The Europe Huntington's Disease Treatment Market is projected to witness market growth of 8.8% CAGR during the forecast period (2024-2031).
The Germany market dominated the Europe Huntington's Disease Treatment Market by Country in 2023, and is forecast to continue being a dominant market till 2031; thereby, achieving a market value of $51.95 millions by 2031. The UK market is exhibiting a CAGR of 7.9% during (2024 - 2031). Additionally, The France market is projected to experience a CAGR of 9.7% during (2024 - 2031).
Disease-modifying therapies aim to alter the course of Huntington’s Disease by targeting the underlying genetic and biological mechanisms driving neurodegeneration. The goal of antisense oligonucleotide (ASO) and RNA interference (RNAi) therapy is to decrease the generation of mutant huntingtin protein (mHTT), which is neurotoxic. These therapies slow disease progression by lowering mHTT levels in the brain. Also, CRISPR/Cas9 and other gene editing approaches can potentially edit the mutant HTT gene directly, correcting the genetic mutation responsible for HD or modifying its expression.
Supportive care strategies are integral to managing the complex needs of HD patients and addressing the disease’s broader impact on their lives. HD patients benefit from care provided by multidisciplinary teams, including neurologists, genetic counselors, psychiatrists, physical therapists, occupational therapists, and social workers. This comprehensive approach addresses HD’s diverse medical, psychological, and social aspects.
The UK develops specialized healthcare services and infrastructure to meet the needs of individuals with HD. This includes HD clinics staffed by multidisciplinary teams of neurologists, genetic counselors, psychologists, and social workers. These clinics provide comprehensive care and support tailored to the complex needs of HD patients and their families. As per Brain Research UK, around 7,000 people are living with Huntington’s disease (HD) in the UK. In conclusion, the prevalence of Huntington’s disease in the region is driving the market's growth.
The Germany market dominated the Europe Huntington's Disease Treatment Market by Country in 2023, and is forecast to continue being a dominant market till 2031; thereby, achieving a market value of $51.95 millions by 2031. The UK market is exhibiting a CAGR of 7.9% during (2024 - 2031). Additionally, The France market is projected to experience a CAGR of 9.7% during (2024 - 2031).
Disease-modifying therapies aim to alter the course of Huntington’s Disease by targeting the underlying genetic and biological mechanisms driving neurodegeneration. The goal of antisense oligonucleotide (ASO) and RNA interference (RNAi) therapy is to decrease the generation of mutant huntingtin protein (mHTT), which is neurotoxic. These therapies slow disease progression by lowering mHTT levels in the brain. Also, CRISPR/Cas9 and other gene editing approaches can potentially edit the mutant HTT gene directly, correcting the genetic mutation responsible for HD or modifying its expression.
Supportive care strategies are integral to managing the complex needs of HD patients and addressing the disease’s broader impact on their lives. HD patients benefit from care provided by multidisciplinary teams, including neurologists, genetic counselors, psychiatrists, physical therapists, occupational therapists, and social workers. This comprehensive approach addresses HD’s diverse medical, psychological, and social aspects.
The UK develops specialized healthcare services and infrastructure to meet the needs of individuals with HD. This includes HD clinics staffed by multidisciplinary teams of neurologists, genetic counselors, psychologists, and social workers. These clinics provide comprehensive care and support tailored to the complex needs of HD patients and their families. As per Brain Research UK, around 7,000 people are living with Huntington’s disease (HD) in the UK. In conclusion, the prevalence of Huntington’s disease in the region is driving the market's growth.
List of Key Companies Profiled
- Bausch Health Companies, Inc.
- Teva Pharmaceutical Industries Ltd.
- Camber Pharmaceuticals, Inc. (Hetero Labs Limited)
- Hikma Pharmaceuticals PLC
- Takeda Pharmaceutical Company Limited
- Sun Pharmaceutical Industries Ltd.
- Dr.Reddy’s Laboratories Ltd.
- Neurocrine Biosciences Inc.
- Pfizer, Inc.
- F.Hoffmann-La Roche Ltd.
Market Report Segmentation
By Drug Type- Approved Drugs
- Tetrabenazine
- Deutetrabenazine
- Offlabel Drugs
- Hospital Pharmacies
- Drug Store & Retail Pharmacies
- Online Pharmacies
- Below 50 years
- Above 50 years
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Europe Huntington’s Disease Treatment Market by Drug Type
Chapter 5. Europe Huntington’s Disease Treatment Market by Distribution Channel
Chapter 6. Europe Huntington’s Disease Treatment Market by Age
Chapter 7. Europe Huntington’s Disease Treatment Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Bausch Health Companies, Inc.
- Teva Pharmaceutical Industries Ltd.
- Camber Pharmaceuticals, Inc. (Hetero Labs Limited)
- Hikma Pharmaceuticals PLC
- Takeda Pharmaceutical Company Limited
- Sun Pharmaceutical Industries Ltd.
- Dr. Reddy’s Laboratories Ltd.
- Neurocrine Biosciences Inc.
- Pfizer, Inc.
- F. Hoffmann-La Roche Ltd.
Methodology
LOADING...
